Case report: new treatment with Tolvaptan for heart failure after cardiac surgery.

@article{Sezai2014CaseRN,
  title={Case report: new treatment with Tolvaptan for heart failure after cardiac surgery.},
  author={Akira Sezai and Mitsuru Iida and Isamu Yoshitake and Shunji Osaka and Hiroaki Hata and Motomi Shiono},
  journal={The heart surgery forum},
  year={2014},
  volume={17 4},
  pages={
          E198-200
        }
}
The vasopressin V2 receptor antagonist (Tolvaptan) is a new diuretic that selectively promotes the excretion of water. It has been reported to be effective for patients in cardiology, but there have been no reports of its use in the perioperative period after cardiac surgery. We report the usefulness of Tolvaptan for postoperative fluid management in a patient with severe mitral regurgitation due to ischemic cardiomyopathy. Marked improvement was achieved after administration of Tolvaptan for… 
View on PubMed
doi.org

References

SHOWING 1-9 OF 9 REFERENCES
New treatment with human atrial natriuretic peptide for postoperative myonephropathic metabolic syndrome.
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
TLDR
In patients hospitalized with heart failure, oral tolvaptan in addition to standard therapy including diuretics improved many, though not all, heart failure signs and symptoms, without serious adverse events.
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
TLDR
Tolvaptan initiated for acute treatment of patients hospitalized with heart failure had no effect on long-term mortality or heart failure-related morbidity.
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
Results of low-dose carperitide infusion in high-risk patients undergoing coronary artery bypass grafting.
Relation of loop diuretic dose to mortality in advanced heart failure.
Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction.
Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization.
Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.
TLDR
Responsible response to TLV can be predicted using U-OSM, which can be estimated using urine urea nitrogen, sodium, and creatinine concentration data.